Systemic Lupus Erythematosus study: ABBV-519
Official title A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
ClinicalTrials.gov ID: NCT07607964
What this study is testing
What is ABBV-519?
ABBV-519 is an investigational medicine being studied as a potential treatment for systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA).
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether ABBV-519 is safe and how it moves through the body in adults with lupus or rheumatoid arthritis.
- Who it's for
- You may be able to join if you are an adult with moderate lupus or rheumatoid arthritis.
- What's involved
- You will receive a single dose of ABBV-519 by IV or injection. You will have hospital visits for blood tests, exams and questionnaires.
- Time commitment
- The study lasts about 425 days, with a 60‑day screening, a 1‑day treatment and 52 weeks of follow‑up visits.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Individuals between 18 and 75 years of age inclusive at the time of Screening.
- Clinical diagnosis of SLE and fulfilling the 2019 EULAR/ACR classification criteria.
- Positive ANA ≥ 1:80 and the presence of at least one of the following autoantibodies above the upper limit of normal (ULN): anti-double-stranded DNA...
- Hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI) score of ≥ 4 (excluding anti-dsDNA and C3/C4).
- Clinical diagnosis of RA and fulfilling the 2010 ACR/EULAR classification criteria for RA.
You likely can't join if
- Participants with a history of infection.
- Active neuropsychiatric SLE, or signs or symptoms of neuropsychiatric SLE within the 6 months prior to Screening (lupus headache permissible).
- SLE overlap syndromes including, but not limited to RA, Sjogren's disease (SjD), SSc, polymyositis, dermatomyositis, or mixed connective tissue...
See the full eligibility criteria
- Individuals between 18 and 75 years of age inclusive at the time of Screening.
- Clinical diagnosis of SLE and fulfilling the 2019 EULAR/ACR classification criteria.
- Positive ANA ≥ 1:80 and the presence of at least one of the following autoantibodies above the upper limit of normal (ULN): anti-double-stranded DNA (dsDNA), anti-Smith (Sm), anti-ribonucleoprotein (RNP), or...
- Hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI) score of ≥ 4 (excluding anti-dsDNA and C3/C4).
- Clinical diagnosis of RA and fulfilling the 2010 ACR/EULAR classification criteria for RA.
- Presence of rheumatoid factor (RF) or anti-citrullinated peptide antibodies (ACPA) above the ULN.
- Presence of at least 6 swollen and 6 tender joints
- High-sensitivity C-reactive protein (hs-CRP) ≥ 3 mg/L.
- Failed at least 1 conventional synthetic disease-modifying antirheumatic drug (DMARD) and ≥ 1 biological or targeted DMARDs of different classes.
- Participants with a history of infection.
- Active neuropsychiatric SLE, or signs or symptoms of neuropsychiatric SLE within the 6 months prior to Screening (lupus headache permissible). \- Unstable or progressive glomerulonephritis (active class III or IV).
- SLE overlap syndromes including, but not limited to RA, Sjogren's disease (SjD), SSc, polymyositis, dermatomyositis, or mixed connective tissue disease.
The study team makes the final eligibility decision.
Where it is enrolling
- Anniston, Alabama, United States
- Tustin, California, United States
- Clearwater, Florida, United States
- Greenacres City, Florida, United States
- Kissimmee, Florida, United States
- Miami, Florida, United States
- Plantation, Florida, United States
- Tampa, Florida, United States
- Orland Park, Illinois, United States
- Jackson, Tennessee, United States
- Houston, Texas, United States
- Red Oak, Texas, United States
- Nagoya, Aichi-ken, Japan
- Bunkyo-ku, Tokyo, Japan
- Shinjuku-ku, Tokyo, Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Anniston, Alabama, United States; Tustin, California, United States; Clearwater, Florida, United States; Greenacres City, Florida, United States; Kissimmee, Florida, United States; Miami, Florida, United States and 9 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.